{"groups":[{"description":"ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg\n\nASP7487, Velcade, Dexamethasone: ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration","id":"FG000","title":"ASP7487, Velcade, Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Available drug expired on 31 May 16"}],"milestones":[{"achievements":[{"comment":"Phase I study part stopped early due to manufacturer's decision to stop further drug development.","groupId":"FG000","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"comment":"3 patients taken off study due to non-availability of further study (Linsitinib) drug supply.","groupId":"FG000","numSubjects":"16"}],"comment":"Phase II part of the study not done due to termination of further study drug development.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Subject enrollment under this IND was stopped prematurely due to the drug manufacturer's decision to terminate the development of the study drug, Linsitinib (letter dated 1 November 2015). Therefore, the study did not proceed to Phase II portion of the study protocol. The available study drug supply at the study sites expired on 31 May 2016."}